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Abstract
Dysregulation of miRNAs is a hallmark of cancer, modulating oncogenes, tumor suppressors, and drug responsiveness.
The multi-kinase inhibitor sorafenib is one of the first-line drugs for advanced hepatocellular carcinoma (HCC),
although the outcome for treated patients is heterogeneous. The identification of predictive biomarkers and targets of
sorafenib efficacy are sorely needed. Thus, selected top upregulated miRNAs from the C19MC cluster were analyzed in
different hepatoma cell lines compared to immortalized liver human cells, THLE-2 as control. MiR-518d-5p showed the
most consistent upregulation among them. Thus, miR-518d-5p was measured in liver tumor/non-tumor samples of
two distinct cohorts of HCC patients (n= 16 and n= 20, respectively). Circulating miR-518d-5p was measured in an
independent cohort of HCC patients receiving sorafenib treatment (n= 100), where miR-518d-5p was analyzed in
relation to treatment duration and patient’s overall survival. In vitro and in vivo studies were performed in human
hepatoma BCLC3 and Huh7 cells to analyze the effect of miR-518d-5p inhibition/overexpression during the response
to sorafenib. Compared with healthy individuals, miR-518d-5p levels were higher in hepatic and serum samples from
HCC patients (n= 16) and in an additional cohort of tumor/non-tumor paired samples (n= 20). MiR-518d-5p, through
the inhibition of c-Jun and its mitochondrial target PUMA, desensitized human hepatoma cells and mouse xenograft
to sorafenib-induced apoptosis. Finally, serum miR-518d-5p was assessed in 100 patients with HCC of different
etiologies and BCLC-stage treated with sorafenib. In BCLC-C patients, higher serum miR-518d-5p at diagnosis was
associated with shorter sorafenib treatment duration and survival. Hence, hepatic miR-518d-5p modulates sorafenib
resistance in HCC through inhibition of c-Jun/PUMA-induced apoptosis. Circulating miR-518d-5p emerges as a
potential lack of response biomarker to sorafenib in BCLC-C HCC patients.
Introduction
Hepatocellular carcinoma (HCC) is the sixth most
common cancer worldwide and the third leading cause of
cancer-related death1,2. Despite recent progress in HCC
treatment, long-term survival and the well-being of the
patients remain poor. Sorafenib is one of the first-line
systemic drugs for HCC treatment; although the survival
benefit for patients is heterogeneous and depends on their
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baseline characteristics3,4. Recognizing signaling networks
to improve and predict the activity of sorafenib and
identifying the cause of drug resistance would be highly
beneficial to guide a personalized HCC treatment and to
determine the outcome of patients enrolled in clinical
trials. Sorafenib inhibits several tyrosine kinase receptors,
such as those triggering the RAF and MEK/ERK path-
ways5, the platelet-derived growth factor receptor
(PDGFR), and vascular endothelial growth factor recep-
tors (VEGFRs)6. Besides its antiangiogenic and anti-
proliferative effect, the pro-apoptotic effects of sorafenib
have been reported to occur by different mechanisms,
including downregulating of induced myeloid leukemia
cell differentiation protein (MCL-1)7 and increasing the
expression of the p53-upregulated modulator of apoptosis
(PUMA, BBC3), which functions as a critical initiator of
apoptosis in cancer cells8,9. Besides P53, BBC3 tran-
scription is also regulated by p53-independent pathways,
including transcription factors, such as Foxo3A, C/EBP,
E2F1, and c-Jun8–11. PUMA can promote apoptosis by
inhibiting anti-apoptotic molecules of the Bcl2 family or
by activating pro-apoptotic BAX-BAK proteins, leading to
mitochondrial membrane permeabilization (MMP)8,12,13.
A number of reports have described an essential role for
the activation of the JNK/c-Jun pathway in the apoptotic
and antiproliferative response to sorafenib, despite the
controversy pertaining c-Jun function in cell cycle pro-
gression and HCC initiation14–17.
MiRNAs regulate biological processes including differ-
entiation and metabolism, as well as cellular responses
such as proliferation, apoptosis, and tumorigenesis18,19. In
the liver, miRNA signatures have been associated with
non-alcoholic fatty liver disease (NAFLD), cirrhosis, and
liver cancer20–27. Different miRNAs have been associated
with the development of resistance to chemotherapeutic
agents and, notably, to sorafenib28–33. The biological
significance and therapeutic potential of miRNAs in liver
disease management are rapidly growing fields of
research. In particular, miRNAs belonging to C19MC, the
largest human miRNA cluster, have been reported to be
overexpressed in certain HCC patients and to have pro-
tumorigenic and metastatic activity34. In this context, we
aimed to identify miRNAs overexpressed in HCC that
could contribute to tumor development and potentially
regulate sorafenib resistance.
In this study, we report that hepatic and circulating
miR-518d-5p levels are increased in human HCC. High
circulating miR-518d-5p levels are associated with shorter
sorafenib treatment duration and decreased overall sur-
vival in the Barcelona clinic for liver cancer (BCLC)-C
HCC patients. Likewise, miR-518d-5p over-expression is
associated with sorafenib resistance in human hepatoma
cells and an experimental mouse xenograft model in vivo.
c-Jun was identified as a miR-518d-5p target involved in
the regulation of apoptosis following sorafenib adminis-
tration. A complex regulatory network in the modulation
of sorafenib response is presented, based on associations




All patients in the study gave informed consent to all
clinical investigations, according to the principles embo-
died in the Declaration of Helsinki.
miR-518d-5p expression in liver and serum of patients with
HCC
miR-518d-5p levels were determined in liver tissue and
paired serum samples from patients with HCC, cirrhosis,
and healthy individuals of the Donostia University Hos-
pital (San Sebastian, Spain). The clinical information of
the study population is provided in Supplementary Table I
and II. The project was approved by the Ethical Review
Board of participating Institutions.
miR-518d-5p expression in non-tumor (NT)/tumor (T)
matched tissues from HCC patients
miR-518d-5p levels were determined in NT-T matched
tissue samples obtained from ultrasonographic (US)-gui-
ded liver biopsy from 20 patients enrolled by Modena
Hospital with liver cirrhosis and HCC detected during
surveillance35. In brief, patients with compensated liver
cirrhosis and HCC lesions detected under US surveillance
underwent a dedicated imaging protocol (two computed
tomography exams 6-weeks apart in absence of any other
therapy to evaluate growth speed) and a US-guided liver
biopsy. After the second computed scan, patients under-
went therapy according to internationally accepted
guidelines.
miR-518d-5p levels in serum from HCC patients treated
with sorafenib
Circulating miR-518d-5p levels were determined in two
different cohorts of patients. The first study was approved
by the Newcastle and North Tyneside Regional ethics
committee, the Newcastle academic health partners
bioresource (NAHPB), and the Newcastle upon Tyne
NHS Foundation Trust Research and Development
(R&D) department (References 10/H0906/41; NAHPB
Project 48; REC 12/NE/0395; R&D 6579; Human Tissue
Act license 12534). Serum samples of 16 patients were
obtained from patients who received sorafenib between 1
February 2010 to 31 July 2017, who consented to the use
of their surplus tissues initially obtained for diagnostic
requirements for research purposes. All patients had a
confirmed diagnosis and management of HCC according
to standard European guidelines36. Patient demographics
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and clinicopathological information including age, sex,
underlying liver disease etiology, combined BCLC stages,
treatments administered, and response to treatment are
summarized in Supplementary Table III (right column,
Newcastle). Of the 16 patients studied, nine of them
received sorafenib after TACE treatment, while seven
received it as their first treatment. The median time to
start sorafenib following the bio banked serum sample
was 3.67 months (range 0.07–17.63). The median dura-
tion of treatment (400 mg twice daily) was 6.71 months
(range 4.38–13.66 months). Survival data were recorded
for all patients until 30 August 2018. Clinical parameters
are summarized in Supplementary Table III (right col-
umn, Newcastle).
The second cohort of serum samples from 84 patients
treated with sorafenib was from the Barcelona clinic liver
cancer (BCLC) group, at Hospital Clinic (Barcelona,
Spain) and this study was approved by the Hospital Clinic
of Barcelona ethics committee (2012/7635). Clinical
parameters are summarized in Supplementary Table III
(left column, BCLC). In brief, 50 of the 84 received sor-
afenib after surgery or TACE treatment, while 34 received
it as the first treatment. The median duration of the
treatment was 6.15 months (IQR 2.94–10.64) and the
median follow-up of patients was 11.13 months (IQR
6.89–20.04).
Statistical analysis
Laboratory data are represented as mean ± SEM. Data
are represented as fold change referred to non-treated
control conditions. Statistical differences were measured
using an unpaired two-sided Student t-test or the Welch’s
test whenever unequal variances were found or paired t-
test as indicated. Clinical data are represented as a median
and interquartile range [IQR 25th–75th percentiles] for
continuous or ordinal variables, and absolute frequency
and percentages (%) for categorical. Nonparametric tests
(U Mann–Whitney test or Wilcoxon signed-rank test for
paired analysis) were used for continuous or ordinal
variables, except in cases where the data shows a normal
distribution, specifically evaluated in each case by histo-
grams. Differences between categorical variables were
assessed by Pearson Chi-square, or Fisher exact test when
appropriate. Time to event variables was described using
the Kaplan–Meier method and the survival functions
were compared with the log-rank test. Hazard ratios (HR)
and their 95% confidence intervals (95%) were estimated
with survival Cox models. For statistically significant Cox
models, the sensitivity, specificity, area under the curve
(AUC), and their 95%CI were estimated in relevant time-
points. Also, Harrell’s c-statistic concordance and their
95%CI were estimated.
Statistical analyses on Newcastle patients were per-
formed with SPSS, version 21 (SPSS Inc. Chicago, USA)
licensed to Newcastle University, and on BCLC patients,
the statistical analyses were performed with SAS 9.4 soft-
ware (SAS Institute, Cary, NC, USA). The level of sig-
nificance was set at the two-sided 5% level.
Animals
A xenograft murine model was established by injecting
≈5 × 106 Huh7 hepatoma cells into both flanks of NU
(NCr)-Foxn1nu athymic nude female mice (n= 5,
4 months old, male). One week after cell injection, tumor
masses were monitored and when the tumors reached a
volume of ≈200mm3, mice received a daily dose of sor-
afenib (15mg/kg body weight, intragastrically) for 3 weeks
or less until the tumors reached 2000mm3. MiR control
(miR-Ctrl) or miR-518d-5p was overexpressed directly by
intratumoral injection (10 µg/tumor, twice a week) at each
flank with jetPEI (Polyplus). Mice were euthanized at the
end of the treatment or when the tumor exceeded
2000 mm3. Tumor volume was calculated according to
the formula: volume= (a × b2)/2, where “a” is the largest
diameter and “b” is the perpendicular diameter. At
sacrifice, tumors were collected for both molecular biol-
ogy and histopathology. CIC bioGUNE’s Animal Care and
Use Committee and the competent authority (Diputación
de Bizkaia) approved the animal procedures.
Studies in HCC cell lines
In vitro experiments were performed using the human
hepatoma BCLC3 cell line, obtained and characterized as
previously reported37. The THLE2, Huh7, PLC, and
HepG2 cell lines were purchased from ATCC. To carry
out in vitro miR-518d-5p inhibition and overexpression,
human hepatoma BCLC3 and Huh7 cells were transfected
with miRIDIAN microRNA Hairpin Inhibitor/Mimic
miR-518d-5p or an unrelated miR-Ctrl using Dharma-
FECT transfection reagent (Dharmacon, USA) at 25 nM
in the culture medium following the manufacturer’s
procedure. The study of the response to sorafenib treat-
ment in hepatoma cell lines was carried out using BCLC3
and Huh7 hepatoma cells that were cultured with 10 µM
of sorafenib (Selleckchem, USA) for 24 h in a 10% FBS
culture medium. Cellular assays were performed at least
three times independently. A minimum of three replicates
was included per experiment
Luciferase reporter assays
Human c-Jun 3′UTR clone in pMirTarget (cat. number
SC213791) and empty vector pMiRTarget (cat. number
PS100062) were purchased from OriGene (USA). BCLC3
and Huh7 cells were transfected with the pMir or pMir-c-
Jun-3′UTR vectors together with miRIDIAN microRNA
Hairpin Inhibitor/Mimic miR-518d-5p or scrambled
siRNA using the DharmaFECT Duo Transfection Reagent
(Dharmacon), respectively. Firefly luciferase activity was
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determined in cell lysates with the Dual-GLO luciferase
assay system (Promega, USA).
Studies with mitochondria: ROS, membrane potential, and
colocalization
Mitochondrial reactive oxygen species (ROS) produc-
tion was determined by MitoSOX Red mitochondrial
superoxide indicator (Invitrogen, USA). Cultured cells
were loaded with 2 μM MitoSOX Red (10 min, 37 °C in a
CO2 incubator). Cells were then washed with PBS and
fluorescence was read at 510/595 nm (excitation/emis-
sion) using a SpectramaxM2 (Molecular Devices, USA).
Mitochondrial membrane potential was determined using
Tetramethylrhodamine (TMRM) indicator (Invitrogen).
Cultured cells were collected and incubated in PBS with
TMRM 0.5 µM (30min, 37 °C in a CO2 incubator).
Fluorescence was read at 548/574 nm (excitation/emis-
sion) using a SpectramaxM2 (Molecular Devices). Total
mitochondria were determined by MitoTracker® Green
FM (Invitrogen) staining following the manufacturer’s
recommendations. Cultured cells were loaded with
100 nM MitoTracker® Green FM (15min, 37 °C in a CO2
incubator). Cells were washed and directly analyzed at the
microscope or fixed with 4% paraformaldehyde for sub-
sequent mitochondrial-PUMA colocalization studies.
PUMA staining was performed at 1:200; overnight; 4 C
(Cell Signaling 4976) and developed with secondary
Rabbit-Cy3 (1:500; 2 h; RT). Pictures were taken with an
Axio Imager D1 Upright Fluorescence Microscope (Carl
Zeiss AG, Jena, Germany). Quantification of PUMA-
MitoTracker® Green co-staining was performed using the
Frida Software (FRamework for Image Dataset Analysis)
http://bui3.win.ad.jhu.edu/frida/. Change in % area
respect untreated control is represented in the figures.
Real-time respiration studies using Seahorse analyzer
technologies
The cellular metabolic profile was determined using a
Seahorse XFe24 Analyzer (Seahorse Biosciences, USA),
providing real-time measurements of the oxygen con-
sumption rate (OCR) as previously described27. In total,
7–8 × 103 cells were plated and transfected in an XF24 cell
culture microplate (Seahorse Bioscience) for 16 h (over-
night). Then, media was changed and, the next day, Sea-
horse analysis was performed. Real-time respiration assays
were performed using Agilent seahorse DMEM, without
bicarbonate and supplemented with, glutamine (1 mM),
glucose (10 mM), sodium pyruvate (2 mM). Different
assays with or without sorafenib (10 µM) were done. All
the pharmacologic inhibitors were administered through
cartridges with injector ports on the XF sensor, thus,
modulating respiration directly into the cell well during the
assay. After analysis, cell density was evaluated by crystal
violet, and this value was used to normalize readings.
For the XF Cell Mito Stress Test Kit, used as described
in the User Guide (Kit 103015-100, Agilent), the following
pharmacologic inhibitors were used: oligomycin (1 μM),
for the ATP-coupled oxygen consumption; carbonyl
cyanide 4-trifluoromethoxyphenylhydrazone (FCCP)
(300 nM), an uncoupling agent that allows maximum
electron transport, showing the maximal OXPHOS
respiration capacity; and Rotenone (1 µM)/Antimycin
(1 µM) mix as a mitochondrial complex I and III inhibi-
tors, respectively.
For the ATP production rate, the assay was assessed
simultaneously from glycolysis and mitochondria using
label-free technology XF Real-Time ATP Rate Assay kit as
described in the User Guide (Kit 103592-100, Agilent).
The following pharmacologic inhibitors were used: oli-
gomycin (1 µM) and Rotenone (1 µM)/Antimycin
(1 µM) mix.
Cell death and viability analyses
Cell death/viability was determined by two different
methods. Cell death was determined by AnnexinV ana-
lysis using flow cytometry. Briefly, cells were collected and
pelleted for subsequent staining in 100 µl of AnnexinV
Buffer with 2 µl of propidium iodide (PI) and 2 µl of
AnnexinV (FITC) for 15min, at RT, protected from light
(BD Biosciences, USA). Stained cells were analyzed in a
FACS Canto Cytometer (BD Biosciences).
For viability analyses, cells were stained and fixed with
0.1% Crystal violet in 20% methanol solution at RT for
40min. Then cells were washed and dried and incubated
in 10% acetic acid for 1 h at RT and finally measured using
a Spectramax M3 spectrophotometer.
RNA isolation and quantitative real-time PCR
RNA was isolated with Trizol (Invitrogen), and its
concentration and integrity were determined. PCRs were
performed using iQ™ SYBR® Green Supermix (Biorad)
and the Bio-Rad iCycler thermocycler (Bio-Rad, Hercules,
CA). The Ct values were extrapolated to a standard curve,
and data was then normalized to the housekeeping
expression (ARP).
Protein isolation and western blotting
Extraction of total protein from cultured cells and livers
was performed as described38. In total, 4–25 µg of protein
were electrophoresed on sodium dodecyl sulfatepolya-
crylamide gels and transferred onto membranes. Band
intensities were quantified using the ImageJ software and
normalized to the β-ACTIN housekeeping.
Immunohistochemistry
Paraffin-embedded liver samples were sectioned,
dewaxed, and hydrated. Immunohistochemistry was per-
formed as previously described39.
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TUNEL immunofluorescence
Tumor paraffin-embedded tissue sections were first
dewaxed and hydrated, then were stained using in situ cell
death detection kit (Roche). Briefly, samples were incu-
bated 3% H2O2 (diluted in MeOH), second, 20 min of
incubation with Proteinase K to unmask or display the
epitopes. Finally, we incubate the enzyme 2 h at 37°,
samples were mounted with DAPI. Ten to twenty random
images per sample were taken with a ×20 objective in
Upright Fluorescent Microscope (Axioimager D1). The
stained area percentage of each sample was calculated
using FIJI (ImageJ) https://imagej.net/Fiji.
MiRNA quantitative real-time PCR
RT-PCR was performed for miR-518d-5p following a
TaqMan® MicroRNA Reverse Transcription Kit (Life
Technologies, USA) procedure using 10–50 ng of total
RNA. qPCR was performed with the TaqMan Universal
PCR Master Mix No AmpErase UNG kit following the
manufacturer’s procedure. miR-518d-5p expression levels
were normalized with the U6 snRNA.
MiRNA isolation and quantification in serum
MiRNA was isolated from serum with the miRNeasy
Serum/Plasma Kit (Qiagen, Germany) following the
manufacturer’s procedure. RT/q-PCR was performed as
described above. miR-518d-5p levels were normalized
with the miR-39 Spike-In Control for the Newcastle and
Barcelona BCLC cohorts and with Spike-In sp4 for heal-
thy and HCC patients from the Donostia University
Hospital.
Supplemental material
Detailed material of the study is provided in the Sup-
plemental material document.
Results
miR-518d-5p is overexpressed in human hepatoma cells
The relevance of microRNAs in diagnosis and prognosis
in HCC is rapidly growing. Notably, the largest human
miRNA cluster, C19MC, has been reported to be altered
in HCC patients with protumorogenic and metastatic
activity34,40. Consequently, we selected five top up-
regulated miRNAs from the C19MC described to be
involved in HCC40. Selected miRNAs were miR-518d–5p,
miR-515-3p, miR-518a-3p, miR-520f, miR-525-3p
(Fig. 1A). To screen for the potential value of these
microRNAs as therapeutic targets in HCC, we first ana-
lyzed their expression levels in different hepatoma cell
lines compared to the immortalized liver human control
cell line, THLE-2. MiR-518d-5p had the most consistent
upregulation between the different hepatoma cell lines
while others were not consistently altered or were even
decreased (Fig. 1B). With this premise, we focused on
miR-518d-5p to further study its role in HCC. Thus, we
evaluated miR-518d-5p levels in tissues from 36 patients
with HCC. These included a cohort of 16 patients with
HCC of diverse etiology, in which miR-518d-5p was
overexpressed compared with healthy subjects (Fig. 1C)
(Supplementary Table I). Similarly, in an independent
validation cohort of 20 HCC patients35 (baseline-paired
HCC and surrounding tissue), increased miR-518d-5p in
liver tumors was confirmed (Fig. 1D).
Increased serum miR-518d-5p levels are associated with
HCC
Finding new biomarkers to attend to the needs asso-
ciated with personalized treatments is a challenge in the
oncology field. To examine whether miR-518d-5p is a
feasible circulating marker, we analyzed serum miRNA
levels from healthy, cirrhotic, and HCC patients.
Increased circulating miR-518d-5p levels were detected in
the 12 HCC patients whose hepatic levels had been
evaluated previously (Fig. 1C), as compared to 10 healthy
individuals and 15 cirrhotic patients (Fig. 1E). Thus,
increased miR-518d-5p serum levels may have value as an
HCC biomarker.
miR-518d-5p regulates mitochondrial functionality in
human hepatoma cells
Cancer cells are more sensitive to the rapid increase in
ROS than normal cells41. Therefore, abnormal production
of ROS could trigger cell cycle arrest and apoptosis, with
the direct participation of mitochondria42–44. Results in
Fig. 2A indicate that in human hepatoma BCLC3 cells
transfected with anti-miR-518d-5p (Supplementary Fig.
1A), mitochondrial ROS levels were elevated (Fig. 2A). The
increase in ROS production is in accordance with a higher
respiratory capacity after anti-miR-518d-5p administration
(Fig. 2A). The quantification of ATP production rate from
glycolysis and mitochondria using label-free technology
revealed no significant changes in BCLC3 control versus
anti-miR-518d-5p cells, albeit a tendency for increased
ATP production is detected (Fig. 2A). Moreover, blocking
miR-518d-5p induced JNK activity and increased levels of
c-Jun at the mRNA and protein levels (Fig. 2B, Supple-
mentary Fig. 1B). As a consequence, proliferation, anti-
apoptotic markers, and survival were reduced whilst genes
and proteins related to apoptosis were induced (Fig. 2B
and Supplementary Fig. 1B).
Next, we determined whether increasing miR-518d-5p
levels induced relevant changes in hepatoma cell behavior.
To address this, a mimic-miR-518d-5p was transfected
into Huh7 human hepatoma cells, where miR-518d-5p
expression is much lower than in the BCLC3 cells (Fig. 1B
and Supplementary Fig. 1C). Mitochondrial analysis
revealed decreased respiratory capacity, ROS production,
and lower ATP production from glycolysis and
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mitochondria (Fig. 2C). MiR-518d-5p-overexpressing
cells showed decreased JNK activation, accompanied by
increased BrdU and cell viability. Downregulation of c-Jun
and other genes related to cell cycle inhibition and
apoptosis were also identified in the presence of miR-
518d-5p in Huh7 cells. These data further support that
this miRNA participates in the regulation of these pro-
cesses in HCC (Fig. 2D, Supplementary Fig. 1D).
miR-518d-5p desensitizes liver tumor to sorafenib induced
cell death through mitochondrial activity
The role of miRNAs and mitochondria in conferring
drug resistance and susceptibility to apoptotic response
has been described by several studies42–44. To study the
role of miR-518d-5p in mitochondrial functionality and its
link to sorafenib-induced apoptosis we designed two dif-
ferent strategies combining anti- or mimic- miR-518d-5p
with different time points of sorafenib administration.
Apoptosis was studied after 24 h of sorafenib exposure,
while mitochondrial functionality was analyzed from 5min
to 3 and 24 h of sorafenib administration (Supplementary
Fig. 2A). BCLC3 cells with higher miR-518d-5p levels were
more resistant to sorafenib treatment than Huh7 cells
(Supplementary Fig. 2B). Sorafenib-incubated BCLC3 cells
transfected with anti-miR-518d-5p increased (1.4-fold) the
proportion of apoptotic cells (AnnexinV/PI) (Fig. 3A).
Sorafenib causes apoptosis by inducing mitochondrial
stress and ATP depletion in hepatoma cells45–47. Notably,
combined sorafenib (24 h) plus anti-miR-518d-5p in
BCLC3 cells potentiated mitochondrial stress and a four-
fold increase in ROS production (MitoSOX) (Fig. 3B). In
agreement, different Bcl-2-related anti- and pro-apoptotic
genes (MCL-1, BCL2, NOXA, BID, BAD, BAX, and
PUMA) were regulated after anti-miR-518d-5p and sor-
afenib treatment (Figs. 3C and 5A). To determine the
involvement of mitochondrial dysfunction in sorafenib
induced cell death in our model, ROS was assessed at
shorter times (10min and 3 h) after sorafenib treatment, a
time-point where cell death is still not significant (data not
shown), revealing enhanced ROS production in anti-miR-
518d-5p hepatoma cells (Fig. 3D). In addition, no differ-
ences in mitochondrial transmembrane potential (ΔΨm)
Fig. 1 Hepatic and circulating miR-518d-5p levels in hepatocellular carcinoma patients. A Schematic representation of the C19MC microRNA
cluster, highlighting the five miRNAS analyzed. B Heat map depiction of the levels of the five miRNAs analyzed in the indicated cell lines. C MiR-518d-
5p RNA expression in liver biopsies from a cohort of healthy and HCC patients (Mann–Whitney test), and in a second cohort (D) of HCC patients of
non-tumoral tissue (NT) and tumoral tissue (T) liver biopsies (Wilcoxon signed-rank test). E Serum circulating levels of miR-518d-5p in healthy cirrhotic
and HCC patients. Data presented as mean ± SEM. *p < 0.05; **p < 0.01.
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were observed at 5 and 10min of sorafenib treatment,
while prolonged exposure rendered a reduction on it in
the presence of anti-miR-518d-5p in BCLC3 cells (Sup-
plementary Fig. 3A, E). This effect could be produced by
an impairment in the respiratory chain. Thus, the anti-
miR-518d-5p treatment plus sorafenib was evaluated by
seahorse. Although in these circumstances, anti-miR-
518d-5p increased OCR that could explain the higher
Fig. 2 Experimental manipulation of miR-518d-5p expression affects the oncogenic capacity of human hepatoma cell lines. Anti/mimic-
miR-518d-5p (25 nM, 48 h) effect in BCLC3 and Huh7 hepatoma cells. A Determination of oxygen consumption rate (OCR), mitochondrial ROS
(MitoSOX) production, and dual ATP production (glycolysis and mitochondria) levels in BCLC3 cells under miR-518d-5p inhibition. B Determination of
proliferation (BrdU), survival (Crystal violet), and gene expression (qPCR) of indicated genes in BCLC3 under miR-518d-5p inhibition. C Determination
of oxygen consumption rate (OCR), mitochondrial ROS (MitoSOX) production, and dual ATP production (glycolysis and mitochondria) levels in Huh7
cells under miR-518d-5p overexpression. D Determination of proliferation (BrdU), survival (Crystal violet), and gene expression (qPCR) of indicated
genes in Huh7 cells under miR-518d-5p overexpression. Data normalized as fold change vs. control where indicated. Data presented as mean ± SEM.
p < 0.05; *p < 0.01; **p < 0.001.
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mitochondrial ROS production and the consequent cyto-
toxic effects, sorafenib treatment produced more pro-
nounced OCR reduction as a readout of impairment in
mitochondrial respiration (Supplementary Fig. 3C).
On the contrary, experimental overexpression of miR-
518d-5p in Huh7 cells reduced apoptosis by FACS-
AnnexinV analysis and improved survival upon sorafenib
treatment (Fig. 4A). MiR-518d-5p overexpression in
Huh7 sorafenib treated cells (24 h) corroborated these
data with a reduction close to fourfold in mitochondrial
ROS (Fig. 4B). This effect was again accompanied by the
regulation of different Bcl-2-related genes involved in cell
death (Fig. 4C). Moreover, the reduction of mitochondrial
ROS, increase of ΔΨm at 3 h, and the reduction of
respiratory capacity in hepatoma cells treated with sor-
afenib plus miR-518d-5p during short time periods (3 h)
indicated resistance to sorafenib (Supplementary Figs. 3B,
D and 4D, E). Respiration studies showed the opposite
effect to sorafenib treatment in miR-518d-5p Huh7
overexpressing cells (Supplementary Fig. 3D), further
supporting the role of miR-518d-5p in the regulation of
mitochondrial function.
Overall, our results indicate that miR-518d-5p induces
sorafenib resistance in hepatoma cells. Mitochondrial
activity was lower in the presence of elevated miR-518d-
5p levels, associated with reduced ROS production and a
chemoresistance phenotype.
miR-518d-5p targets c-Jun and PUMA in human hepatoma
cells
c-Jun has been previously implicated in sorafenib-
induced apoptosis14–17. Upregulation of c-Jun and
PUMA was the readout of the combinatory anti-miR-
518d-5p plus sorafenib in BCLC3 cells (Figs. 5A and 6A),
while the overexpression of mimic-miR-518d-5p in the
presence of sorafenib resulted in a reduction of both
apoptotic markers in Huh7 (Fig. 5B). Indeed, chemore-
sistant BCLC3 cells showed half of the levels of c-Jun
compared to Huh7 cells (Supplementary Fig. 4A, B).
PUMA has been described as the major regulator of
apoptotic processes, maintaining mitochondrial outer
membrane integrity. PUMA translocation from the cyto-
sol to mitochondria has been shown to promote apop-
tosis12. Moreover, PUMA regulates apoptosis in
hepatoma cells incubated with sorafenib9,16. Using fluor-
escence microscopy, we detected that the increase in
PUMA observed in BCLC3 cells subjected to anti-miR-
518-5p plus sorafenib occurred predominantly in mito-
chondria (Fig. 5C). The opposite effect was detected in
Huh7 cells overexpressing miR-518d-5p under sorafenib,
where PUMA levels diminished in mitochondria as
showed by co-staining with MitoTracker (Fig. 5D). This
suggests a complex regulation of mitochondrial function
mediated by miR-518d-5p that may involve cJUN
and PUMA.
Fig. 3 Inhibition of miR-518d-5p enhances sorafenib-induced cell death and mitochondrial dysfunction in human hepatoma cells. A Cell
viability analysis after sorafenib treatment (24 h, 10 µM) measured by AnnexinV (left) and crystal violet (right). Characterization of sorafenib effect (24 h,
10 µM) by (B) mitochondrial ROS production (mitoSOX) and (C) gene expression analysis. Determination of mitochondrial function by (D) ROS
production (mitoSOX) and (E) mitochondrial membrane potential (TMRE) at indicated short times of sorafenib treatment. *p < 0.05; **p < 0.01;
***p < 0.001. (*miR-Ctrl vs. anti-miR-518d-5p; # compares sorafenib vs. non-treated ctrl cells. Data presented as mean ± SEM).
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To clarify the mechanisms underlying miR-518d-5p’s
effect on c-Jun and PUMA, an in silico analysis was per-
formed with miRWALK and RNA22 databases to look for
predicted miR-518d-5p binding sites in c-Jun or PUMA,
identifying a potential target site for miR-518d-5p within
the 3′UTR of c-Jun (Supplementary Fig. 5A). To prove a
direct interaction between miR-518d-5p and c-Jun, the 3′
UTR region of this gene was cloned and the resulting
vector (pMir-c-Jun-3′UTR) was employed in a dual-
luciferase assay. The cotransfection of the pMiR-c-Jun-3′
UTR vector into BCLC3 cells with anti-miR-518d-5p
resulted in an increase of the 3′UTR-c-Jun luciferase
expression (Fig. 5E). On the contrary, 3′UTR-c-Jun
expression in Huh7 cells overexpressing miR-518d-5p
decreased luciferase activity (Fig. 5F). Both results confirm
miR-518d-5p as a direct repressor of c-Jun in these
human hepatoma cell lines. Therefore, targeting miR-
518d-5p, which induces the c-Jun-PUMA axis, represents
a novel mechanism to induce apoptosis in hepatoma cells
and enhance the response to sorafenib.
c-Jun and PUMA are the effectors of the apoptotic
response mediated by miR-518d-5p regulation
To demonstrate that c-Jun targeting is an important
mechanism mediating sorafenib resistance by miR-518d-
5p in BCLC3 cells, we silenced c-Jun with siRNAs. Cells
were transfected with anti-miR-518d-5p and a siRNA for
c-Jun and treated with sorafenib. By Immunoblot and
qPCR analysis, we observe that silencing c-Jun blocked its
increase following anti-miR-518d-5p exposure (Fig. 6A).
As expected, c-Jun inhibition decreased mRNA and pro-
tein levels of its target PUMA (Fig. 6A). Importantly, c-
Jun silencing and PUMA reduction significantly coun-
teracted sorafenib-induced apoptosis in anti-miR-518d-5p
treated cells (Fig. 6B). Interestingly, we also observed a
regulation in the anti-apoptotic mitochondrial marker
MCL-1, reinforcing the regulation of apoptosis mediated
by miR-518d/c-Jun in hepatoma cells under sorafenib
treatment (Fig. 6C).
We further evaluated the relevance of mitochondria
functionality when we silenced c-Jun in combination with
anti-miR-518d-5p. Silencing of c-Jun and the described
downregulation of PUMA was associated with a reduction
of mitochondrial ROS at 24 h and at shorter times (3 h) of
sorafenib treatment, even under miR-518d-5p inhibition
(Fig. 6D). Reinforcing these results, the loss of mito-
chondrial transmembrane potential (ΔΨm) produced after
blocking miR-518d-5p in the presence of sorafenib was
avoided when c-Jun and PUMA levels were specifically
reduced (Fig. 6E). This indicates that the mitochondrial
effect of anti-miR-518d-5p was mainly due to c-Jun-
PUMA regulation. Considering the importance of PUMA
Fig. 4 Overexpression of miR-518d-5p induces sorafenib resistance in human hepatoma cells. A Cell viability analysis after sorafenib treatment
(24 h, 10 µM) measured by AnnexinV (left) and crystal violet (right). Sorafenib effect (24 h, 10 µM) by (B) mitochondrial ROS production (mitoSOX) and
(C) gene expression analysis. Determination of mitochondrial function by analysis of (D) ROS production (mitoSOX) and (E) mitochondrial membrane
potential (TMRE) at 3 h of sorafenib treatment. p < 0.05.; *p < 0.01; **p < 0.001. (*miR-Ctrl vs. mimic-miR-518d-5p; # compares sorafenib vs. non-treated
ctrl cells. Data are represented as fold change referred to the non-treated control condition. Data presented as mean ± SEM).
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Fig. 5 Involvement of miR-518d-5p/c-Jun/PUMA axis in sorafenib-induced cell death in hepatoma cells. WB and qPCR analysis of c-Jun and
PUMA in (A) BCLC3 and (B) Huh7 hepatoma cells under sorafenib treatment (24 h, 10 µM) and miR-518d inhibition/overexpression. Analysis of PUMA
mitochondrial subcellular localization by double PUMA/MitoTracker staining under 3 h of sorafenib treatment in BCLC3 (C) and (D) Huh7 cells during
miR-518d-5p inhibition/overexpression. Luciferase reporter assay of c-Jun-3′UTR in (E) BCLC3 and (F) Huh7 hepatoma cell lines after miR-518d-5p
inhibition and overexpression, respectively. Normalized data referred to untreated control in each cell line. *p < 0.05; **p < 0.01; ***p < 0.001. (*miR-
Ctrl vs. miR-518d-5p; # compares sorafenib vs. non-treated ctrl cells. Data are represented as fold change referred to the non-treated control
condition. Data presented as mean ± SEM).
Fernández-Tussy et al. Cell Death and Disease          (2021) 12:555 Page 10 of 16
Official journal of the Cell Death Differentiation Association
Fig. 6 Specific silencing of c-Jun reverts anti-miR-518d-5p proapoptotic effect in BCLC3 cells. A WB and qPCR analysis of c-Jun and PUMA in
BCLC3 after sorafenib treatment (24 h, 10 µM) and miR-518d-5p inhibition and silencing of c-Jun. B Cell death analysis measured by AnnexinV and
crystal violet and (C) qPCR analysis of indicated survival-related genes in response to miR-518d-5p inhibition and c-Jun silencing in sorafenib treated
cells (24 h, 10 µM). Determination of (D) mitochondrial ROS production and (E) mitochondrial membrane potential after sorafenib treatment at
indicated time points. F Analysis of PUMA mitochondrial subcellular localization by double PUMA/MitoTracker staining in sorafenib-treated cells (3 h,
10 µM). G Summary of the proposed model of miR-518d-5p role in sorafenib resistance in HCC through inhibition of c-Jun-mediated mitochondrial
dysfunction and apoptosis. *p < 0.05; **p < 0.01; ***p < 0.001.# compares sorafenib vs. non-treated ctrl cells. Data are represented as fold change
referred to the non-treated control condition. Data presented as mean ± SEM.
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mitochondrial localization in the apoptotic response
mediated by anti-miR-518d-5p, both parameters were
evaluated after c-Jun silencing in BCLC3 cells. The
PUMA/Mitotracker double staining revealed a reverse
effect to that previously observed (Fig. 5C, D) under miR-
518d-5p inhibition in sorafenib-treated BCLC3 cells when
c-Jun was also inhibited (Fig. 6F). These data demonstrate
that miR-518d-5p directly represses c-Jun expression in
human hepatoma cells and that c-Jun and its target gene
PUMA are specifically involved in miR-518d-5p-mediated
sorafenib resistance through the regulation of mitochon-
drial functionality (Fig. 6G).
Finally, we studied the extent of apoptosis in response to
sorafenib due to anti-miR-518d-5p or c-Jun comparing
survival rate in cells treated either with anti-miR-518d-5p
or overexpressing c-Jun. Our results show that although
c-Jun overexpression (Supplementary Fig. 6A) is sufficient
to induce sorafenib mediated apoptosis, this effect is not
as high as the anti-miR-518d-5p response, suggesting
other miR-518d-5p targets may also be involved in sor-
afenib induced apoptosis (Supplementary Fig. 6B).
MiR-518d-5p overexpression promotes sorafenib
resistance in vivo
To directly confirm the role of miR-518d-5p in sor-
afenib resistance we employed a xenograft model using
Huh7 cells, which are sensitive to sorafenib and express
low miR-518d-5p. Tumors were induced at both flanks of
the mice and after their formation, miR-Ctrl was induced
in one flank tumor, while miR-518d-5p expression was
induced in the other, after which mice received a daily
dose of sorafenib. Tumor growth and the response to
sorafenib were followed for 3 weeks (Fig. 7A). miR-518d-
5p overexpression counteracted the effect of sorafenib on
tumor growth compared to miR-Control tumors (Fig. 7B).
Histological analysis also revealed different effects of
sorafenib on proliferation and cell survival/apoptosis, as
observed by the decreased necrotic areas and terminal
deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) positive cells in the miR-518d-5p over-
expressing tumors, together with increased pan-RAS and
proliferating cell nuclear antigen (PCNA) (Fig. 7C). These
results further suggest a role of miR-518d-5p in resistance
to sorafenib-induced apoptosis and growth arrest. Indeed,
the activity of ERK and S6 as markers of survival and
proliferation were upregulated in miR-518d-5p tumors
(Fig. 7D). Remarkably, c-Jun and its targets PUMA, as well
as other BCL2 family proteins, were decreased in miR-
518d-5p overexpressing tumors (Fig. 7D, E), indicating
the anti-apoptotic role of miR-518d-5p.
In summary, the results obtained in this xenograft
mouse model provided evidence for an in vivo role of
miR-518d-5p in sorafenib drug resistance inferring a
modulatory response in mitochondria activity.
High circulating miR-518d-5p is associated with a poor
response to sorafenib treatment
We evaluated miR-518d-5p levels in the sera of 100
patients, including 84 from Barcelona and an independent
cohort of 16 patients from Newcastle, using the log value
to approximate normality (Supplementary Table III). The
underlying etiologies in the Barcelona cohort of patients
were mainly viral and alcohol-related, classified as BCLC
B and C, while patients from Newcastle predominantly
had NAFLD-HCC, classified as BCLC-C. Treatment
duration and overall survival time were analyzed based on
serum miR-518d-5p levels as a categorical variable,
dividing patients into two groups according to the median
level of miR-518d-5p (8.84 [0.4–315.05] in all cohort). In
the whole combined cohort, patients with miR-518d-5p
levels above the median showed a tendency to shorter
treatment duration (4.81 [IQR: 2.43–9.8] vs. 7.84 [IQR:
4.57–12.43] months, p= 0.07) but not in survival (10.90
(95%CI: 6.54–13.58) vs. 12.39 (95%CI: 10.59–16.17)
months, p= 0.16) compared to patients with low miR-
518d-5p circulating levels (Supplementary Table IV). In
the BCLC-C patient’s group, the differences between high
and low circulating miR-518d-5p were significantly
greater, with a treatment duration of 4.46 [IQR:
1.61–7.76] vs. 8.02 [IQR: 4.57–13.64] months (p= 0.006)
and survival of 6.49 (95%CI: 4.40–12.75) vs. 12.39 (95%CI:
8.81–17.09) months (p= 0.033), with an estimated HR of
1.73 (95%CI: 1.04–2.90, p-value= 0.036) (Supplementary
Table IV) with a C-statistic of 0.59 (95%CI: 0.52–0.66)
(Supplementary Table V). In contrast, no significant dif-
ferences were found in BCLC-B patients. These data
suggest that the circulating levels of miR-518d-5p could
be considered as a useful tool to predict sorafenib
response in terms of survival in HCC BCLC-C patients.
Discussion
Changes in miRNA expression are associated with HCC
progression18,20,25,40,48. The C19MC miRNA cluster
includes a set of miRNAs frequently upregulated in HCC
and other cancers34,49. Nowadays, a clinical challenge in
the oncology field, and more specifically in HCC, is the
identification of non-invasive biomarkers for prognostic
stratification and precision of treatments. Of special
relevance is the finding of predictive non-invasive markers
of drug resistance to sorafenib, the first-line systemic drug
for HCC treatment, and more ambitiously, the quest for
innovative approaches that may modulate the response to
sorafenib, and thereby their potential use in combina-
tional therapies. In this regard, miRNAs have been linked
to the development of resistance to chemotherapeutic
agents and, particularly, to sorafenib28–33,44. Consistent
with other C19MC miRNAs reported previously, our
results show increased miR-518d-5p levels in hepatic
tumors and serum of HCC patients. Moreover, we provide
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Fig. 7 MiR-518d-5p promotes in vivo sorafenib resistance in HCC. A Time scheme of xenograft model. B Tumor volume fold increment in miR-
Ctrl/miR-518d-5p xenograft tumors. C H&E, TUNEL, pan-RAS, and PCNA staining in tumor sections of xenografts tumors. D WB analysis with indicated
antibody and (E) mRNA expression analysis of proteins and genes implicated in sorafenib antiproliferative and proapoptotic effect in murine
xenografts. *p < 0.05; **p < 0.01. Data are represented as fold change referred to as control. Data presented as mean ± SEM.
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functional evidence that miR-518d-5p can participate in
sorafenib resistance during HCC through enhanced cell
proliferation and decreased sorafenib-induced apoptosis.
The mechanisms underlying miR-518d-5p-related sor-
afenib drug resistance were explored.
Different mechanisms of resistance to sorafenib include
reduced drug uptake50, unresponsiveness to sorafenib by
upregulation of Mcl17, downregulation of PUMA9, and
desensitization to TGFβ16. PUMA has been proposed as
the main mediator of sorafenib-induced apoptosis and can
be regulated by different mechanisms including NF-κB
and c-Jun9,10,16. Indeed, PUMAmitochondrial localization
triggers an apoptotic response modulating mitochondrial
membrane potential12. Our results showed a correlation
between PUMA levels, mitochondrial respiration, func-
tionality, ROS production, and response to sorafenib
under anti-miR-518d-5p treatment in BCLC3 cells.
Indeed, inhibiting miR-518d-5p in the presence of sor-
afenib promotes a more pronounced reduction in
respiratory activity as a readout of electron transport
chain functionality. Thus, mitochondrial activity appears
as a predictive marker for the response of tumor cells to
sorafenib. These results are in agreement with previous
studies linking oxidative phosphorylation with mito-
chondrial dysfunction and sorafenib resistance in hepa-
toma cells51.
Interestingly, a database analysis revealed c-Jun as a
potential target of miR-518d-5p, which was confirmed
in vitro. Our results indicate a complex regulatory net-
work in the modulation of sorafenib response in vitro and
in preclinical animal models between the miR-518d-5p, c-
Jun, and its target PUMA. Of note, silencing c-Jun after
miR-518d-5p inhibition abrogated the apoptotic response
to sorafenib, coinciding with a decrease in the induction
of PUMA. These results are in line with previous studies
involving c-Jun in PUMA transactivation and apoptosis in
hepatocytes and in hepatoma cells treated with sor-
afenib10,16. Moreover, this reinforces the positive role of
the JNK/c-Jun pathway activation by sorafenib and other
anticancer drugs in the regulation of apoptosis in
HCC11,14,15,17. In the context of mitochondrial activity,
miR-518d-5p confers a survival advantage to liver cancer
cells enhancing their buffer capacity against ROS, main-
taining membrane integrity, and avoiding apoptosis.
Our data also suggest that miR-518d-5p levels are a
promising non-invasive clinical risk factor of the response
of HCC patients to sorafenib. Clinical factors associated
with a better outcome to sorafenib include lower tumor
burden, lack of portal invasion, lack of extrahepatic dis-
ease, as well as HCV-HCC rather than other etiologies52.
Additional predictive biomarkers based on biological
traits would be helpful for all patients, but perhaps more
so for the growing number of NAFLD-HCC patients,
where the chance of benefit is lower and the drug is less
well tolerated due to poorer performance status test (PST)
and comorbidities. Our results support a tendency of
higher risk in advanced HCC, classified as BCLC-C,
although it has a low individual prediction capacity, with a
C-statistic of 0.59 (0.52–0.66). Further analysis would be
required to confirm this tendency. The significantly
shorter treatment duration and survival in NAFLD-HCC
patients versus other etiologies may all be stage-asso-
ciated, but it is also known that mitochondrial dysfunc-
tion is one of the main mechanisms associated with
NAFLD53. Hence, it is possible that the impact of miR-
518d-5p on mitochondrial activity and ROS varies in the
different HCC etiologies under sorafenib treatment.
In summary, our results indicate that sorafenib resis-
tance in liver cancer may be due in part to high miR-
518d-5p expression. This is translated into the repression
of c-Jun and the inability to efficiently induce transcrip-
tion PUMA. In turn, decreased PUMA levels lead to
membrane potential increase and decreased ROS pro-
duction that dimmed cancer cell apoptosis by maintaining
mitochondrial membrane potential and ROS production
at sustained levels. Inhibition of miR-518d-5p loses c-Jun/
PUMA repression, triggering the apoptotic process in
hepatoma cells. Thus, we propose that strategies aiming at
inhibiting miR-518d-5p may contribute to overcoming
HCC resistance to sorafenib.
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